[{"orgOrder":0,"company":"Cebina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Azelastine Hydrochloride","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cebina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cebina \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cebina \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr Reddy\u2019s Lab","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Dr Reddy\u2019s Lab"}]

Find Clinical Drug Pipeline Developments & Deals for Azelastine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The divested brand and its extensions represent two types of products, (a) Mometasone mono product and (b) combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

                          Brand Name : Momat Rino Advance

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 28, 2020

                          Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Dr. Reddy\'s Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The potent anti-SARS-CoV-2 activity of azelastine formulated in a nasal spray was demonstrated in an experimental reconstituted human nasal tissue model and was evident at a lower dose than present in commercially available products.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 17, 2020

                          Lead Product(s) : Azelastine Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank